- Home
- INMB vs ANL Comparison
INMB vs ANL Comparison
Compare INMB & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- ANL
- Stock Information
- Founded
- INMB 2015
- ANL 2004
- Country
- INMB United States
- ANL Cayman Islands
- Employees
- INMB N/A
- ANL N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- INMB Health Care
- ANL
- Exchange
- INMB Nasdaq
- ANL Nasdaq
- Market Cap
- INMB 68.9M
- ANL 56.0M
- IPO Year
- INMB 2019
- ANL 2023
- Fundamental
- Price
- INMB $2.91
- ANL $1.42
- Analyst Decision
- INMB Buy
- ANL Hold
- Analyst Count
- INMB 4
- ANL 1
- Target Price
- INMB $9.53
- ANL N/A
- AVG Volume (30 Days)
- INMB 4.5M
- ANL 6.1K
- Earning Date
- INMB 08-04-2025
- ANL 08-08-2025
- Dividend Yield
- INMB N/A
- ANL N/A
- EPS Growth
- INMB N/A
- ANL N/A
- EPS
- INMB N/A
- ANL N/A
- Revenue
- INMB $50,000.00
- ANL N/A
- Revenue This Year
- INMB $203.60
- ANL N/A
- Revenue Next Year
- INMB $13,122.47
- ANL N/A
- P/E Ratio
- INMB N/A
- ANL N/A
- Revenue Growth
- INMB N/A
- ANL N/A
- 52 Week Low
- INMB $1.89
- ANL $1.10
- 52 Week High
- INMB $11.64
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- INMB 41.06
- ANL 40.84
- Support Level
- INMB $2.62
- ANL $1.48
- Resistance Level
- INMB $3.07
- ANL $1.55
- Average True Range (ATR)
- INMB 0.25
- ANL 0.05
- MACD
- INMB 0.24
- ANL -0.00
- Stochastic Oscillator
- INMB 72.26
- ANL 2.27
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.